BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26235184)

  • 1. Biomarkers to detect Wilms tumors in pediatric patients: where are we now?
    Charlton J; Pavasovic V; Pritchard-Jones K
    Future Oncol; 2015; 11(15):2221-34. PubMed ID: 26235184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol.
    Vujanić GM; Gessler M; Ooms AHAG; Collini P; Coulomb-l'Hermine A; D'Hooghe E; de Krijger RR; Perotti D; Pritchard-Jones K; Vokuhl C; van den Heuvel-Eibrink MM; Graf N;
    Nat Rev Urol; 2018 Nov; 15(11):693-701. PubMed ID: 30310143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting.
    Brok J; Mavinkurve-Groothuis AMC; Drost J; Perotti D; Geller JI; Walz AL; Geoerger B; Pasqualini C; Verschuur A; Polanco A; Jones KP; van den Heuvel-Eibrink M; Graf N; Spreafico F
    Eur J Cancer; 2021 Feb; 144():113-122. PubMed ID: 33341445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
    Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
    Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B; Williams R; Ridolfi A; A'hern R; Warren W; Tinworth L; Hobson R; Al-Saadi R; Whyman G; Brundler MA; Kelsey A; Sebire N; Jones C; Vujanic G; Pritchard-Jones K;
    Eur J Cancer; 2009 Mar; 45(5):819-26. PubMed ID: 19231157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification for wilms tumor: current approach and future directions.
    Dome JS; Perlman EJ; Graf N
    Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group.
    Jackson TJ; Brisse HJ; Pritchard-Jones K; Nakata K; Morosi C; Oue T; Irtan S; Vujanic G; van den Heuvel-Eibrink MM; Graf N; Chowdhury T;
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29702. PubMed ID: 35587187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-tumor genetic heterogeneity in Wilms tumor samples.
    de Sá Pereira BM; Azevedo RM; Aguirre Neto JC; Menezes CF; Rodrigues KE; Faria PA; Camargo B; Maschietto M
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1496-1501. PubMed ID: 31994632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of treatment for Wilms tumor.
    Green DM
    J Pediatr Surg; 2013 Jan; 48(1):14-9. PubMed ID: 23331787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
    van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
    Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
    Perlman EJ; Grundy PE; Anderson JR; Jennings LJ; Green DM; Dome JS; Shamberger RC; Ruteshouser EC; Huff V
    J Clin Oncol; 2011 Feb; 29(6):698-703. PubMed ID: 21189373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Wilms' tumor: reached progress and future prospects].
    Tamaro P
    Arch Ital Urol Androl; 1997 Sep; 69(4):227-32. PubMed ID: 9417294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.
    Watson JA; Bryan K; Williams R; Popov S; Vujanic G; Coulomb A; Boccon-Gibod L; Graf N; Pritchard-Jones K; O'Sullivan M
    PLoS One; 2013; 8(1):e53417. PubMed ID: 23308219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches to risk stratification for Wilms tumor.
    Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
    Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT 2001 trial.
    Jackson TJ; Williams RD; Brok J; Chowdhury T; Ronghe M; Powis M; Pritchard-Jones K; Vujanić GM;
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27627. PubMed ID: 30761727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.